Date: 10 March 2025


Dataset Title: MiGHT Baseline Survey Data


Dataset Creators: Delacroix,E.; Austin, S.


Dataset Contact: MiGHT Study Team: mightstudy@med.umich.edu


Funding: National Institutues of Health (NIH) U-01 Grant


Key Points:
- Survey responses of adults, at increased risk of hereditary cancer, regarding views on barriers and motivators to hereditary genetic testing uptake.


Research Overview:
As part of recruitment for MiGHT, a large clinical trial evaluating interventions to promote uptake of genetic testing for cancer susceptibility, adults were invited to complete a family health history survey tool eliciting detailed family history of cancer diagnoses in first- and second-degree relatives. Sites of subject recruitment included community oncology practices in the state of Michigan, cancer registries, oncology, gastroenterology, and primary care clinics at an academic medical center, community health fairs, and radio and newspaper advertisements.


Methodology:
As part of recruitment for MiGHT, a large clinical trial evaluating interventions to promote uptake of genetic testing for cancer susceptibility, adults were invited to complete a family health history survey tool eliciting detailed family history of cancer diagnoses in first- and second-degree relatives. Sites of subject recruitment included community oncology practices in the state of Michigan, cancer registries, oncology, gastroenterology, and primary care clinics at an academic medical center, community health fairs, and radio and newspaper advertisements. Regardless of sex assigned at birth, all participants were shown all cancer types (bladder, breast, cervical, colorectal, endometrial, lung, melanoma, ovarian, pancreatic, prostate, and ten others) and patients could report multiple primary cancers.

 The University of Michigan Medical School Institutional Review Board approved this research (HUM00180616, HUM00217689, HUM00231415). MiGHT is registered with clinical trials.gov (NCT05162846). 

Individuals whose personal and/or family cancer histories met clinical guidelines-based criteria for genetic testing (GT) (n=3001) received an email invitation from the study team with a unique link to complete a brief survey to assess eligibility for the clinical trial.  Individuals who had already completed GT (n=932), or had an GT appointment scheduled (n=64), or did not have access to a phone or internet (n=155), were under age 18 (n=1), did not communicate in English (n=7), or were deceased (n=15) were excluded and 832 individuals completed informed consent for the trial. 

Consented subjects (n=832) were asked to complete a baseline survey which included questions about hereditary GT knowledge, receipt of clinician recommendations about GT, and motivators and barriers to genetic testing uptake. Reminder emails to complete baseline were sent 1-day, 3-days, 5-days, and 10-days, following consent. Initially up-to eight, later five, reminder phone calls were made one to three times each week for four weeks.

We examined factors associated with receipt of a clinician recommendation for cancer genetic testing (assessed by self-report) and used Multivariable logistic regression to assess the association of demographic factors, cancer diagnoses and receipt of clinician recommendation for cancer GT.

Data was analyzed using R and SPSS v.29. 


Files contained here:
Raw data file
-might_baseline_processed_data2025-02-24.csv

Survey Questions and Response Options
-Baseline_Codebook.docx

Consent form
-Ame00148625_-_MiGHT_consent-Clean_-_2024.07.15.pdf


Related publication(s):
None published


Use and Access: 
This data set is made available under a Creative Commons Attribution-NonCommercial 4.0 International license (CC BY-NC 4.0).

To Cite Data: 
Delacroix, E., Austin, S., Bacon, E., Rice, J., Hanson, E. N., Stoffel, E. M., Roberts, S., Ulhmann, W., Griggs, J. J., Resnicow, K. MiGHT Baseline Survey Data [Data set], University of Michigan - Deep Blue Data. https://doi.org/10.7302/0tqr-dn38